Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis-Reference-Cited by-同舟云学术

Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis

Published:2018-08-02 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Southern Kevin W¹,Patel Sanjay²,Sinha Ian P¹,Nevitt Sarah J³

Affiliation:

1. University of Liverpool; Department of Women's and Children's Health; Alder Hey Children's NHS Foundation Trust Eaton Road Liverpool Merseyside UK L12 2AP

2. Stepping Hill Hopsital, Stockport NHS Foundation Trust; Poplar Grove Hazel Grove Stockport Cheshire UK SK2 7JE

3. University of Liverpool; Department of Biostatistics; Block F, Waterhouse Building 1-5 Brownlow Hill Liverpool UK L69 3GL

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010966.pub2/epdf/full

Reference136 articles.

1. Lumacaftor, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in CF patients with the F508del-CFTR mutation: phase 2 interim analysis;Boyle;Journal of Cystic Fibrosis,2013

2. The investigational CFTR corrector, VX-809 (lumacaftor) co-administered with the oral potentiator ivacaftor improved CFTR and lung function in F509-8DEL homozygous patients: phase II study results;Boyle;Pediatric Pulmonology,2012

3. VX-809, an investigational CFTR corrector, in combination with VX-770, an investigational CFTR potentiator, in subjects with CF and homozygous for the F508DEL-CFTR Mutation [abstract];Boyle;Pediatric Pulmonology,2011

4. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial;Boyle;The Lancet. Respiratory Medicine,2014

5. Supplementary Appendix to "A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial." [online];Boyle;The Lancet. Respiratory Medicine,2014

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis;Frontiers in Pharmacology;2023-12-14

2. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del);Cochrane Database of Systematic Reviews;2023-11-20

3. Targeted Therapy for Cystic Fibrosis in Children;Innovative Medicine of Kuban;2023-11-17

4. Efficacy of CFTR modulators in clinical practice (6-month follow-up);PULMONOLOGIYA;2023-04-12

5. Successful Modulator Treatment Desensitization in a Patient with Cystic Fibrosis;ASTIM ALLERJI IMMUNO;2023